Cantor Fitzgerald restated their underweight rating on shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) in a report published on Wednesday morning. They currently have a $69.00 price target on the biopharmaceutical company’s stock.

Other equities research analysts have also issued reports about the company. Credit Suisse Group set a $201.00 price objective on Intercept Pharmaceuticals and gave the stock a buy rating in a research note on Saturday, June 3rd. Wells Fargo & Company reissued an outperform rating on shares of Intercept Pharmaceuticals in a research note on Wednesday. BidaskClub raised Intercept Pharmaceuticals from a hold rating to a buy rating in a research note on Friday, June 23rd. Laidlaw reissued a hold rating and set a $119.00 price objective (up from $115.00) on shares of Intercept Pharmaceuticals in a research note on Tuesday, August 1st. Finally, Jefferies Group LLC reissued a buy rating and set a $275.00 price objective on shares of Intercept Pharmaceuticals in a research note on Sunday, July 30th. One research analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $205.48.

Intercept Pharmaceuticals (NASDAQ:ICPT) traded down 4.41% during trading on Wednesday, hitting $86.75. The stock had a trading volume of 1,687,425 shares. The stock’s market cap is $2.18 billion. The firm’s 50-day moving average price is $111.73 and its 200-day moving average price is $116.97. Intercept Pharmaceuticals has a 1-year low of $85.88 and a 1-year high of $172.95.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share for the quarter, topping the consensus estimate of ($3.62) by $0.16. The business had revenue of $30.89 million during the quarter, compared to analyst estimates of $27.50 million. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The company’s revenue was up 459.6% compared to the same quarter last year. During the same period last year, the company posted ($3.14) EPS. On average, equities research analysts predict that Intercept Pharmaceuticals will post ($14.06) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was first posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.dailypolitical.com/2017/09/14/intercept-pharmaceuticals-icpt-underweight-rating-reaffirmed-at-cantor-fitzgerald.html.

In related news, Director Daniel G. Welch sold 217 shares of the stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $126.76, for a total transaction of $27,506.92. Following the completion of the sale, the director now directly owns 3,710 shares in the company, valued at $470,279.60. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Daniel G. Welch sold 602 shares of the stock in a transaction on Monday, July 31st. The stock was sold at an average price of $123.93, for a total value of $74,605.86. Following the sale, the director now owns 3,108 shares of the company’s stock, valued at $385,174.44. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 48,013 shares of company stock valued at $6,198,747. 9.20% of the stock is owned by corporate insiders.

Several large investors have recently made changes to their positions in the stock. PNC Financial Services Group Inc. raised its holdings in shares of Intercept Pharmaceuticals by 0.7% during the first quarter. PNC Financial Services Group Inc. now owns 2,020 shares of the biopharmaceutical company’s stock worth $229,000 after acquiring an additional 14 shares in the last quarter. Public Employees Retirement Association of Colorado raised its holdings in shares of Intercept Pharmaceuticals by 1.1% during the second quarter. Public Employees Retirement Association of Colorado now owns 4,111 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 43 shares in the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of Intercept Pharmaceuticals by 1.8% during the second quarter. Janney Montgomery Scott LLC now owns 3,435 shares of the biopharmaceutical company’s stock worth $416,000 after acquiring an additional 62 shares in the last quarter. WFG Advisors LP raised its holdings in shares of Intercept Pharmaceuticals by 16.4% during the second quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 125 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Intercept Pharmaceuticals by 14.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock worth $118,000 after acquiring an additional 132 shares in the last quarter. Institutional investors and hedge funds own 82.19% of the company’s stock.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.